Claire Harrison

Summary

Affiliation: Guy's and St Thomas' NHS Foundation Trust
Country: UK

Publications

  1. ncbi request reprint Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial
    Claire N Harrison
    Department of Haematology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom
    Semin Thromb Hemost 32:283-8. 2006
  2. doi request reprint Myeloproliferative disorders in pregnancy
    Claire N Harrison
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, Guy s Hospital, London, UK
    Hematol Oncol Clin North Am 25:261-75, vii. 2011
  3. pmc Emerging treatments for essential thrombocythemia
    Steven Okoli
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, Great Maze Pond, London, UK
    J Blood Med 2:151-9. 2011
  4. doi request reprint Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
    Ruben A Mesa
    Haematologica 99:292-8. 2014
  5. doi request reprint Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
    Claire N Harrison
    Guy s and St Thomas NHS Foundation Trust, Guy s Hospital, London, UK
    Br J Haematol 162:229-39. 2013
  6. ncbi request reprint Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
    Claire Harrison
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, UK
    Br J Haematol 157:426-37. 2012
  7. doi request reprint JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    Claire Harrison
    Guy s and St Thomas National Health Service Foundation Trust, Guy s Hospital, London, United Kingdom
    N Engl J Med 366:787-98. 2012
  8. pmc New versus old blood - the debate continues
    John Laurie
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, UK
    Crit Care 14:130. 2010
  9. doi request reprint Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera
    Claire Harrison
    Guy s and St Thomas National Health Service Foundation Trust, London, United Kingdom
    Hematology Am Soc Hematol Educ Program 2010:129-34. 2010
  10. doi request reprint Do we know more about essential thrombocythemia because of JAK2V617F?
    Claire Harrison
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, Lambeth Palace Road, London, SE1 7EH, UK
    Curr Hematol Malig Rep 4:25-32. 2009

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial
    Claire N Harrison
    Department of Haematology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom
    Semin Thromb Hemost 32:283-8. 2006
    ..Cortelazzo et al reported the first study in 1995. The second is the Medical Research Council Primary Thrombocythemia 1 trial (MRC PT-1), the results and implications of which are the subject of this article...
  2. doi request reprint Myeloproliferative disorders in pregnancy
    Claire N Harrison
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, Guy s Hospital, London, UK
    Hematol Oncol Clin North Am 25:261-75, vii. 2011
    ..An outline of the key factors regarding the diagnosis and management of MPN in women of reproductive potential is followed by a description of the authors' management strategy for standard and high-risk pregnancy in MPN patients...
  3. pmc Emerging treatments for essential thrombocythemia
    Steven Okoli
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, Great Maze Pond, London, UK
    J Blood Med 2:151-9. 2011
    ..This study discusses this and recent progress, highlighting exciting new data with old and new drugs, as well as which patients in particular should be evaluated for these new therapies...
  4. doi request reprint Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
    Ruben A Mesa
    Haematologica 99:292-8. 2014
    ..Both COMFORT-I (NCT00952289) and COMFORT-II (NCT00934544) studies have been appropriately registered with clinicaltrials.gov. ..
  5. doi request reprint Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
    Claire N Harrison
    Guy s and St Thomas NHS Foundation Trust, Guy s Hospital, London, UK
    Br J Haematol 162:229-39. 2013
    ..Overall, these data demonstrated that ruxolitinib improved HRQoL in MF patients and further support the use of ruxolitinib for the treatment of symptomatic MF...
  6. ncbi request reprint Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
    Claire Harrison
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, UK
    Br J Haematol 157:426-37. 2012
    ....
  7. doi request reprint JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    Claire Harrison
    Guy s and St Thomas National Health Service Foundation Trust, Guy s Hospital, London, United Kingdom
    N Engl J Med 366:787-98. 2012
    ..Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis...
  8. pmc New versus old blood - the debate continues
    John Laurie
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, UK
    Crit Care 14:130. 2010
    ..Whilst advantageous for the logistics of stock management, the clinical impact of the duration of red blood cell storage prior to transfusion remains uncertain, and a topic of growing interest...
  9. doi request reprint Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera
    Claire Harrison
    Guy s and St Thomas National Health Service Foundation Trust, London, United Kingdom
    Hematology Am Soc Hematol Educ Program 2010:129-34. 2010
    ....
  10. doi request reprint Do we know more about essential thrombocythemia because of JAK2V617F?
    Claire Harrison
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, Lambeth Palace Road, London, SE1 7EH, UK
    Curr Hematol Malig Rep 4:25-32. 2009
    ..As with many important scientific discoveries, however, although the discovery of the JAK2V617F mutation has helped us to move forward, there are many new questions and many old questions still unanswered...
  11. ncbi request reprint Anagrelide for control of thrombocytosis due to myeloproliferative disorders
    Claire N Harrison
    Guy s and St Thomas NHS Foundation Trust, St Thomas Hospital, Lambeth Palace Road, London, UK
    Future Oncol 1:609-18. 2005
    ..This article reviews clinical studies in these patients and discusses the future scope for anagrelide...
  12. ncbi request reprint Mechanism of thrombosis in essential thrombocythaemia
    Claire Harrison
    Department of Haematology, Guy s and St Thomas Hospital NHS Trust
    Haematologica 91:145b. 2006
  13. ncbi request reprint Essential thrombocythaemia: challenges and evidence-based management
    Claire N Harrison
    Department of Haematology, St Thomas Hospital, Lambeth Palace Road, London, UK
    Br J Haematol 130:153-65. 2005
    ....
  14. ncbi request reprint Practical management of patients with myelofibrosis receiving ruxolitinib
    Claire Harrison
    Guy s and St Thomas NHS Foundation Trust, London, UK
    Expert Rev Hematol 6:511-23. 2013
    ....
  15. ncbi request reprint Molecular classification of myeloproliferative neoplasms-pros and cons
    Moosa Qureshi
    Department of Haematology, University College London Hospitals NHS Foundation Trust, University College London Hospital, 250 Euston Road, London, NW1 2PG, UK
    Curr Hematol Malig Rep 8:342-50. 2013
    ..Here, we discuss the pros and cons of a molecular classification and its potential utility in diagnosis, prognosis, and therapeutics...
  16. ncbi request reprint Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis
    Mary F McMullin
    Department of Haematology, Queen s University, Belfast, Belfast City Hospital, Belfast, UK
    Br J Haematol 130:174-95. 2005
  17. ncbi request reprint Improvement of fibrosis in a patient with chronic myeloproliferative disease
    Andrew Retter
    Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, UK
    Br J Haematol 139:350. 2007
  18. pmc Two new mutations in the HIF2A gene associated with erythrocytosis
    Melanie J Percy
    Department of Haematology, Belfast City Hospital, Belfast, Northern Ireland BT9 7AB, United Kingdom
    Am J Hematol 87:439-42. 2012
    ..Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc...
  19. ncbi request reprint Pregnancy and its management in the Philadelphia negative myeloproliferative diseases
    Claire Harrison
    Department of Haematology, Guy s and St Thomas Foundation Trust, St Thomas Hospital, London SE1 7EH, UK
    Br J Haematol 129:293-306. 2005
    ..This data are reviewed and a personal management strategy for pregnancy in MPD proposed...
  20. ncbi request reprint Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
    Claire N Harrison
    Department of Haematology, University of Cambridge, and Addenbrooke s National Health Service Trust, Cambridge, United Kingdom
    N Engl J Med 353:33-45. 2005
    ..We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia...
  21. doi request reprint A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
    Christen L Andersen
    Department of Haematology, Roskilde Hospital, Roskilde, Denmark
    Br J Haematol 162:498-508. 2013
    ..However, vorinostat was associated with significant side effects resulting in a high discontinuation rate. A lower dose of vorinostat in combination with conventional and/or novel targeted therapies may be warranted in future studies. ..
  22. doi request reprint The Role of JAK1/2 Inhibitors in the Treatment of Chronic Myeloproliferative Neoplasms
    Clodagh Keohane
    From the Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, United Kingdom Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Phoenix, AZ
    Am Soc Clin Oncol Educ Book 33:301-5. 2013
    ..Nonetheless, the advent of the JAK inhibitor is a welcome advance and has made a dramatic improvement to the therapeutic landscape of these conditions. ..
  23. doi request reprint Management of myelofibrosis: a survey of current practice in the United Kingdom
    Moosa Rashid Qureshi
    Department of Haematology, Guys and St Thomas NHS Foundation Trust, Guy s Hospital, London, UK
    J Clin Pathol 65:1124-7. 2012
    ..To investigate the experience of clinicians in the management of patients with myelofibrosis, current treatment options and their utility...
  24. ncbi request reprint Review: challenges in the management of thrombocytosis in young patients
    Susan Robinson
    Department of Haematology, St Thomas Hospital, Guy s and St Thomas NHS Foundation Trust, London SE1 7EH, UK
    Clin Adv Hematol Oncol 6:137-8, 141. 2008
  25. pmc A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis
    Melanie J Percy
    Department of Haematology, Belfast City Hospital, Belfast BT9 7AB, Northern Ireland, United Kingdom
    Proc Natl Acad Sci U S A 103:654-9. 2006
    ..Our findings indicate that PHD2 is critical for normal regulation of HIF in humans...
  26. pmc Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy
    Peter J Campbell
    Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
    J Clin Oncol 27:2991-9. 2009
    ..Bone marrow histology reflects underlying disease activity in ET but many morphological features show poor reproducibility...
  27. ncbi request reprint The management and outcome of 18 pregnancies in women with polycythemia vera
    Susan Robinson
    Department of Hematology, Guy s and St Thomas NHS Foundation Trust, London, UK
    Haematologica 90:1477-83. 2005
    ..Polycythemia vera (PV) is rare in women of childbearing age with only 20 previous pregnancies reported...
  28. ncbi request reprint MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
    Philip A Beer
    Department of Haematology, University of Cambridge, Cambridge, United Kingdom
    Blood 112:141-9. 2008
    ..MPL mutations lacked prognostic significance with respect to thrombosis, major hemorrhage, myelofibrotic transformation or survival...
  29. ncbi request reprint V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
    Peter J Campbell
    Department of Haematology, University of Cambridge, United Kingdom
    Blood 107:2098-100. 2006
    ..Patients positive for V617F were less likely to require blood transfusion during follow-up (P = .03). Despite this, patients positive for V617F had poorer overall survival, even after correction for confounding factors (P = .01)...
  30. ncbi request reprint Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study
    Peter J Campbell
    Department of Haematology, University of Cambridge, UK
    Lancet 366:1945-53. 2005
    ..We aimed to assess whether patients with the mutation are biologically distinct from those without, and why the same mutation is associated with different disease phenotypes...
  31. ncbi request reprint Essential thrombocythaemia
    Claire N Harrison
    Department of Haematology, Guy s and St Thomas, NHS Foundation Trust, Lanbeth Palace Road, London SE1 7EH, UK
    Best Pract Res Clin Haematol 19:439-53. 2006
    ....
  32. ncbi request reprint Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
    Peter J Campbell
    Department of Haematology, University of Cambridge, Cambridge, United Kingdom
    Blood 108:3548-55. 2006
    ..In 3 patients the leukemic cells were V617F(-), suggesting that in these patients the leukemia arose in a V617F(-) cell...
  33. ncbi request reprint The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels
    Melanie J Percy
    Department of Haematology, Floor C, Tower Block, Belfast City Hospital, Northern Ireland, UK
    Haematologica 92:1607-14. 2007
    ..The aims of this study were to assess the prevalence of JAK2 exon 12 mutations in IE patients, and to determine the associated clinicopathological features...
  34. ncbi request reprint Essential thrombocythemia
    Claire N Harrison
    Department of Haematology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Hematol Oncol Clin North Am 17:1175-90, vii. 2003
    ..This article discusses diagnostic criteria, clinical features, prognosis, and management...
  35. ncbi request reprint Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
    Bridget S Wilkins
    Department of Cellular Pathology, Newcastle upon Tyne Hospitals National Health Service NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK
    Blood 111:60-70. 2008
    ..This study was registered at http://isrctn.org as #72251782 and at http://eudract.emea.europa.eu/ as #2004-000245-38...
  36. pmc JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
    Linda M Scott
    University of Cambridge, Cambridge, United Kingdom
    N Engl J Med 356:459-68. 2007
    ..However, the molecular basis of these myeloproliferative disorders in patients without the V617F mutation is unclear...
  37. ncbi request reprint Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders
    Nasios Fourouclas
    Haemato oncology, Diagnostic Service, Department, of Haematology, Addenbrooke s, Hospital, Hills Road, Cambridge, CB2 0QQ, UK
    Haematologica 93:1635-44. 2008
    ....
  38. ncbi request reprint Risk factors for thrombosis in essential thrombocythaemia
    Betty Cheung
    Department of Haematology, St Thomas Hospital, London, UK
    Clin Lab 50:149-52. 2004